BETA DRUGS
|
BETA DRUGS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| CEPS(Rs) | 54.42 | 45.79 | 40.74 | 31.78 | 18.42 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 195.25 | 163.43 | 127.82 | 96.05 | 71.37 |
| Tax Rate(%) | 25.54 | 25.26 | 25.18 | 27.62 | 26.50 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 20.59 | 20.29 | 23.39 | 23.23 | 21.31 |
| EBIT Margin(%) | 17.65 | 17.44 | 19.14 | 19.69 | 15.82 |
| Pre Tax Margin(%) | 15.72 | 16.49 | 18.08 | 18.66 | 13.74 |
| PAT Margin (%) | 11.71 | 12.32 | 13.53 | 13.51 | 10.10 |
| Cash Profit Margin (%) | 15.16 | 15.63 | 18.11 | 17.45 | 16.02 |
| Performance Ratios | |||||
| ROA(%) | 11.99 | 15.63 | 16.74 | 17.53 | 10.26 |
| ROE(%) | 23.95 | 26.03 | 28.55 | 30.85 | 18.65 |
| ROCE(%) | 25.23 | 32.74 | 33.94 | 36.38 | 22.17 |
| Asset Turnover(x) | 1.02 | 1.27 | 1.24 | 1.30 | 1.02 |
| Sales/Fixed Asset(x) | 2.83 | 2.83 | 2.50 | 2.57 | 1.94 |
| Working Capital/Sales(x) | 1.59 | 3.17 | 3.51 | 3.83 | 3.34 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.35 | 0.35 | 0.40 | 0.39 | 0.51 |
| Receivable days | 91.57 | 87.61 | 86.71 | 78.48 | 103.42 |
| Inventory Days | 55.19 | 49.64 | 42.67 | 38.24 | 44.62 |
| Payable days | 139.01 | 121.55 | 124.66 | 101.32 | 108.61 |
| Valuation Parameters | |||||
| PER(x) | 45.35 | 31.00 | 19.62 | 21.90 | 9.84 |
| PCE(x) | 35.02 | 25.66 | 14.65 | 16.95 | 6.20 |
| Price/Book(x) | 9.76 | 7.55 | 4.90 | 5.89 | 1.68 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 5.28 | 3.96 | 2.66 | 2.98 | 1.05 |
| EV/Core EBITDA(x) | 23.62 | 19.10 | 11.21 | 12.59 | 4.85 |
| EV/EBIT(x) | 29.93 | 22.73 | 13.89 | 15.11 | 6.66 |
| EV/CE(x) | 5.71 | 6.82 | 4.22 | 4.84 | 1.42 |
| M Cap / Sales | 5.31 | 4.01 | 2.65 | 2.96 | 0.99 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 22.54 | 30.21 | 23.54 | 58.31 | 27.88 |
| Core EBITDA Growth(%) | 32.08 | 13.87 | 23.99 | 72.14 | 37.81 |
| EBIT Growth(%) | 24.01 | 18.64 | 20.08 | 97.06 | 26.18 |
| PAT Growth(%) | 16.42 | 18.62 | 23.73 | 111.76 | 24.53 |
| EPS Growth(%) | 10.87 | 18.62 | 23.73 | 111.76 | 24.53 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.70 | 0.09 | 0.17 | 0.22 | 0.25 |
| Current Ratio(x) | 3.01 | 1.99 | 1.93 | 1.87 | 1.95 |
| Quick Ratio(x) | 2.49 | 1.55 | 1.49 | 1.47 | 1.57 |
| Interest Cover(x) | 9.15 | 18.29 | 18.00 | 19.06 | 7.59 |
| Total Debt/Mcap(x) | 0.07 | 0.01 | 0.03 | 0.04 | 0.15 |
Compare Financial Ratios of peers of BETA DRUGS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BETA DRUGS | ₹2,327.2 Cr | 5.4% | 49.7% | 22.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹449,299.0 Cr | 1.4% | 1.2% | 13.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹174,207.0 Cr | -0.5% | -0.6% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹157,721.0 Cr | 2.1% | 1.5% | 42.2% | Stock Analytics | |
| CIPLA | ₹117,420.0 Cr | 6.4% | 1.6% | -3.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,876.0 Cr | 6.2% | 1.6% | 0.2% | Stock Analytics | |
BETA DRUGS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BETA DRUGS | 5.4% |
49.7% |
22.8% |
| SENSEX | -0.4% |
0.8% |
-5.3% |
You may also like the below Video Courses